Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology · 20.02.2026 · 44 (6) · 476-485
DOI: 10.1200/jco-25-02477 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2026. Verfasst von Jennifer A Woyach und 27 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Comprehensive Cancer Center, Columbus, OH. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Pyrimidines, Pyrazoles, Protein Kinase Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), has shown efficacy and safety in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who received prior covalent BTKi. We report results, to our knowledge, from the first randomized head-to-head comparison of pirtobrutinib versus ibrutinib in BTKi-naïve CLL/SLL in both treatment-naïve (TN) patients and patients with relapsed/refractory (R/R) disease. PATIENTS AND METHODS Patients (N = 662) were randomly assigned 1:1 to receive pirtobrutinib or ibrutinib. All patients were BTKi-naïve. Primary end points were overall response rate (ORR) by independent review committee (IRC) among all randomly assigned patients (intention to treat [ITT]) and in patients with R / R disease. RESULTS The study met its primary end points, demonstrating statistically significant noninferiority (NI) of IRC-ORR for pirtobrutinib versus ibrutinib in both the ITT (87.0% [95% CI, 82.9 to 90.4] v 78.5% [95% CI, 73.7 to 82.9]; ORR ratio = 1.11 [95% CI, 1.03 to 1.19]; two-sided P < .0001) and R/R populations (n = 437; 84.0% [95% CI, 78.5 to 88.6] v 74.8% [95% CI, 68.5 to 80.4]; ORR ratio = 1.12 [95% CI, 1.02 to 1.24]; two-sided P < .0001). In TN patients (n = 225), IRC-ORR was 92.9% (95% CI, 86.4 to 96.9) with pirtobrutinib versus 85.8% (95% CI, 78.0 to 91.7) with ibrutinib. Investigator assessed ORR results were consistent. Investigator-assessed progression-free survival (PFS) favored pirtobrutinib in the ITT (hazard ratio [HR], 0.57 [95% CI, 0.39 to 0.83]), R/R (HR, 0.73 [95% CI, 0.47 to 1.13]), and TN (HR, 0.24 [95% CI, 0.10 to 0.59]) populations. Cardiac adverse event rates of atrial fibrillation/flutter and hypertension were lower with pirtobrutinib. CONCLUSION Pirtobrutinib demonstrated NI of ORR versus ibrutinib, with a favorable early PFS trend, particularly in TN patients, and a favorable safety profile including low rates of atrial fibrillation and hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
- Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.
- Department of Hematology, Cellular Therapies and Internal Medicine, Medical University of Wroclaw, Wroclaw, Poland.
- Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
ORCID-Profile: Jennifer A Woyach, Tomasz Wrobel, Marcelo Capra, Jaroslaw Czyz, Shuhua Yi, Ki-Seong Eom, Anna Panovská, Wojciech Jurczak, Kamel Laribi, Ross Baker, Paula Cramer, Katharine L Lewis, Katherine Bao, Naleen Raj Bhandari, William G Wierda
Zitieren
APA
Woyach, J. A., Qiu, L., Grosicki, S., Wrobel, T., Capra, M., Czyz, J., Yi, S., Eom, K. S., Panovská, A., Jurczak, W., Laribi, K., Jacobasch, L., Baker, R., Agajanian, R., Berkovits, A., Özcan, M., Lepretre, S., Coombs, C. C., Cramer, P., …, & Wierda, W. G. (2026). Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology, 44(6), 476-485. https://doi.org/10.1200/jco-25-02477
Vancouver
Woyach JA, Qiu L, Grosicki S, Wrobel T, Capra M, Czyz J, et al. Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Clinical Oncology. 2026;44(6):476-485. doi:10.1200/jco-25-02477
BibTeX
@article{Woyach2026,
author = {Woyach, Jennifer A and Qiu, Lugui and Grosicki, Sebastian and Wrobel, Tomasz and Capra, Marcelo and Czyz, Jaroslaw and Yi, Shuhua and Eom, Ki-Seong and Panovská, Anna and Jurczak, Wojciech and Laribi, Kamel and Jacobasch, Lutz and Baker, Ross and Agajanian, Richy and Berkovits, Alejandro and Özcan, Muhit and Lepretre, Stéphane and Coombs, Catherine C and Cramer, Paula and Lewis, Katharine L and Hill, Marisa and Bao, Katherine and Bian, Yuanyuan and De Batista Ribeiro, Silvia Ramalho and Bhandari, Naleen Raj and Ruppert, Amy S and Leow, Ching Ching and Wierda, William G},
title = {Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {6},
pages = {476--485},
doi = {10.1200/jco-25-02477}
}
EUVIMED